SP0495 Tumor Suppressor Expression for Cancer Detection and Prognosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating cancer are inadequate for early detection and prognosis, particularly in identifying patients at an early stage to reduce mortality and healthcare costs, and there is a need for less invasive and more effective approaches.
Innovation Solution
The identification of SP0495, a tumor suppressor protein encoded by the ORF2 of the KIAA0495 gene, which is silenced in various cancers due to promoter region hypermethylation, is used for cancer diagnosis, prognosis, and treatment by measuring its expression levels or restoring its function in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If early detection methods are implemented, then cancer mortality is reduced, but diagnostic complexity and cost increase
Solution Approach 1:
The patent extracts and focuses on a single specific biomarker (SP0495 protein or its mRNA) from the complex landscape of cancer diagnostics. By measuring only this one tumor suppressor gene expression level rather than conducting comprehensive multi-marker panels or complex imaging studies, the method achieves reliable early cancer detection while simplifying the diagnostic process and reducing costs.
Solution Approach 2:
The SP0495 biomarker serves as a self-indicating marker where its expression level directly reflects the presence or absence of cancer without requiring complex interpretation. The tumor suppressor gene's natural suppression mechanism in cancer cells creates a built-in diagnostic signal that simplifies detection - healthy cells express the gene while cancer cells silence it, providing an automatic binary indication of cancer status.
2Measurement precision
If invasive diagnostic procedures are used, then diagnostic accuracy is improved, but patient suffering and cost increase
Solution Approach 1:
The patent uses SP0495 expression level as an intermediary biomarker that indirectly indicates cancer presence without requiring direct observation or manipulation of cancer cells. Instead of invasive biopsies or surgical procedures, the method measures the expression level of this specific tumor suppressor gene in accessible samples, providing accurate cancer diagnosis while avoiding patient suffering associated with invasive procedures.
3Productivity
If comprehensive cancer screening is performed, then early detection rate increases, but healthcare cost increases
Solution Approach 1:
The patent extracts diagnostic value from a single specific biomarker (SP0495) rather than employing comprehensive multi-marker screening panels or multiple different diagnostic tests. This focused approach maintains high early detection rates by targeting the specific tumor suppressor gene that is silenced in cancer, while significantly reducing healthcare costs compared to comprehensive screening programs that test multiple markers or use expensive imaging technologies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
SP0495 expression levels serve as a biomarker for early cancer detection and prognosis, and restoring its function inhibits cancer cell growth, inducing apoptosis and cell cycle arrest, providing a less invasive and effective method for cancer management.
Implementation Method 1
CpG islands of the promoter region genomic gene are hypermethylated in biological samples of cancer tissues taken from cancer patients
Data Source
AI summary
The present invention relates to the tumor suppressor SP0495, the expression of which is suppressed in cancers due to increased methylation in the genomic sequence of the promoter region controlling its expression, and therefore provides methods for diagnosing cancer, determining cancer risk, and prognosing cancer mortality in a subject by assessing the level of SP0495 expression in the affected cells or tissues. A kit and device useful for such methods are also provided. In addition, the present invention provides a method for treating cancer by increasing SP0495 expression or activity.